

# AVOIDED COST IN COAGULATION FACTORS IN CONGENITAL COAGULOPATHIES CLINICAL TRIALS

MT Rabuñal Álvarez, E Sánchez-Mira, **P Sánchez-Carballo** ([pablo.sanchez.carballo@sergas.es](mailto:pablo.sanchez.carballo@sergas.es)), S Jimeno-Aguado, M Calvin-Lamas, S González-Piñeiro, MI Martín-Herranz.  
Servicio de Farmacia - Complejo Hospitalario Universitario A Coruña. As Xubias, 84 15006 (A Coruña - Spain).

**Background and Importance** It is necessary know the profitability of clinical trials (CT) due to sponsors provided drugs free of charge, particularly in pathologies which have a high economic impact on hospital budget.

**Aim and Objectives** To quantify the avoided cost (AC) of coagulation factors derived from participation on congenital coagulopathies (CC) CT.

**Materials and Methods** Retrospective, observational study of CT conducted in CC at a tertiary hospital during 2022-2023.

**For the calculation of AC, considered medicinal product and posology that patients received before enrollement in CT and doses they would have received if not enrolled.**

✓ Active CT during the study period in congenital coagulopathies  
✗ CT without included patients

## Data sources

- CT management software
- Pharmacy service management database
- Electronic medical records

## Variables

- Total AC during 2022-2023
- Average AC/CT
- Average AC/patient

## Recorded data

- Sponsor and study design
- Pathology
- Patients included/CT
- Prior treatment (medicinal product and posology) before enrollement in the CT
- Time elapsed from inclusion in the CT to the prescription of a new treatment
- Cost of priot treatment (laboratory purchase price [LPP] + value added tax - applied discounts on LPP)

## Results

- ✓ 5 CT in CC were carried out between 2022-2023  
✗ 1/5 CT excluded for not recruiting patients
- 4/4 included CT open and sponsored by the pharmaceutical industry
- 2 CT studied hemophilia A  
2 CT hemophilia A or B
- 5 patients were enrolled (range 1-2)  
5/5 diagnosed severe hemophilia A
- Standard half-life (SHL) factor VIII (FVIII) in 3 patients  
Extended half-life (EHL) FVIII in 2 patients



➤ **Total AC: 829,545€**

➤ **AC in SHL FVIII: 491,650€**

➤ **AC in EHL FVIII: 337,896€**

➤ **Average AC/CT: 207,386€ (range: 77,064€-453,980€)**

➤ **Average AC/patient: 165,909€ (range: 77,064€-260,832€)**

The total expenditure on FVIII in our hospital between 2022-2023 was 2,065,202€ for SHL FVIII and 4,771,999€ for EHL FVIII, so the 4 included CT represented 23.8% and 7.1% economic savings for hospital, respectively, on the total expense

**Conclusion and Relevance** Avoided cost of medications associated with participation in CT contributes to the sustainability of the healthcare system. Also, CT increase scientific knowledge and allow early access for patients to innovative treatments.